Computational and Pharmacological Target of Neurovascular Unit for Drug Design and Delivery by Islam, M.M. & Mohamed, Z.
Review Article
Computational and Pharmacological Target of
Neurovascular Unit for Drug Design and Delivery
Md. Mirazul Islam and Zahurin Mohamed
Pharmacogenomics Lab, Department of Pharmacology, University of Malaya, 50603 Kuala Lumpur, Malaysia
Correspondence should be addressed to Md. Mirazul Islam; mirazul.du.bc@gmail.com
Received 19 August 2015; Revised 4 October 2015; Accepted 4 October 2015
Academic Editor: Luca Cucullo
Copyright © 2015 Md. M. Islam and Z. Mohamed. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
The blood-brain barrier (BBB) is a dynamic and highly selective permeable interface between central nervous system (CNS) and
periphery that regulates the brain homeostasis. Increasing evidences of neurological disorders and restricted drug delivery process
in brain make BBB as special target for further study. At present, neurovascular unit (NVU) is a great interest and highlighted
topic of pharmaceutical companies for CNS drug design and delivery approaches. Some recent advancement of pharmacology and
computational biology makes it convenient to develop drugs within limited time and affordable cost. In this review, we briefly
introduce current understanding of the NVU, including molecular and cellular composition, physiology, and regulatory function.
We also discuss the recent technology and interaction of pharmacogenomics and bioinformatics for drug design and step towards
personalizedmedicine. Additionally, we develop gene network due to understandNVU associated transporter proteins interactions
that might be effective for understanding aetiology of neurological disorders and new target base protective therapies development
and delivery.
1. Introduction
The human brain is one of the most complex organs com-
posed of around 100 billion neurons and glial cells are 10 to
50 times more than the neurons. Major role of neurons cells
is to transmit information as electric impulses to other nerve,
muscle, or gland cells through special junction called synapse.
The brain and central nervous system (CNS) regulate sensory
input andmotor output as well as coordinating all other body
functions. The interface between CNS and the peripheral
circulatory system functions as a dynamic regulator of ion
balance, a nutrient transport, andmolecular trafficking is his-
torically known as blood-brain barrier (BBB) [1]. Although
the neurons and the glial cells were the traditional spotlight
of neuroscience research, a functional neurovascular unit
(NVU) that regulates cerebral blood flow is a comparatively
new discipline of study in neurophysiology [2]. The NVU is
the integrated system of neuronal and vascular endothelial
cells which controls brain homeostasis by restricting the
entry of large and harmful molecules [3]. Pharmacological
importance of the NVU is gradually increasing given its
notion as a successful target for drug designing for prevention
or treatment of various diseases [4]. Abnormal function
of NVU may cause neurological disorders like Alzheimer’s
disease [5], Parkinson’s disease [6], stroke [7, 8], epilepsy [9],
brain tumours [10], trauma [11], and multiple sclerosis [12].
Any proposed novel drugs for the abovementioned diseases
would not be effective if they could not penetrate the BBB.
Lok et al. [13] discussed major cell types and cell-cell
signalling in the brain related toNVU.McCarty et al. [14] dis-
cussed the protein components of NVU (specially integrins)
that regulate permeability of BBB. Zlokovic [15] discussed
BBB dysfunction and neurodegeneration in Alzheimer’s
disease. Although Vangilder et al. [16] discussed currently
available therapeutics for CNS disease, there are no clear
pharmacological or pharmacodynamics approaches of drug
targets for pharmaceuticals as well as no upcoming disease
prevention strategies. None of the reviews discuss future
prospect of target oriented drug design and computational
strategy of time saving and cost-effectiveness. In this review
wewill discuss NVU, regulation of BBB permeability.We also
will focus on modern pharmacological approaches for target
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Figure 1: Structure of neurovascular unit. The cerebral capillary
endothelial cells (EC) have the tight junction (TJ) that associated
with pericytes (PC) and end foot (EF) of astrocytes (ACs). EC and
PC are surrounded by basal lamina (BL). ACs are the cellular linker
between capillary and neurons. Microglia (MG) are the resident
immunocompetent cells of the brain. The movement of solutes
either is passive, driven by a concentration gradient from plasma
to brain, with more lipid soluble substances entering most easily, or
may be facilitated by passive or active transporters in the endothelial
cell membranes. This figure is adopted from Abbott et al. [19].
(NVU) based drug design and efficient delivery as well as
recent use of bioinformatics tools for in silico modeling and
validation of drugs.
2. Blood-Brain Barrier and NVU
The CNS is the most crucial and sensitive system that needs
“gate keepers” to be protected. The BBB is one of the main
gate keepers of CNS. It is a dynamic system that plays a vital
role for homeostatic aspect of the cerebral microcirculation
[1].The brain capillaries supply blood in proximity to neurons
and the brain endothelium forms the largest interface (known
as BBB) for molecular and cellular exchange [17]. It is now
familiar that the brain endothelium of the BBB acts within
a cellular complex recognized as neurovascular unit (NVU)
(Figure 1), which is composed of a capillary segment with its
associated endothelial cells, pericytes, basement membranes,
perivascular astrocytes, neurons, and microglial cells [18].
The idea of BBB came from variance of dye absorption
between periphery and brain [20]. Goldmann injected trypan
blue into the cerebrospinal fluid (CSF) of mice and noticed
that all brain cells stained but not periphery [21]. So there
must be a barrier and the BBB term was first used by
Lewandowsky [22]. But the controversy of this invisible
barrierwas influenced by the observation of basic aniline dyes
that crossed the barrier, although acidic aniline dyes did not.
Friedemann concluded that electrochemical properties of
the molecules determined the permeability of the capillaries
of the CNS [23]. Molecular weight, molecular size, bind-
ing affinities, dissociation constants, lipid solubility, electric
charge, and various combinations of all of these properties
determined the rate of entry into the brain [24]. Still some
controversy was going on about physical existence of the BBB
[25, 26]. This type of controversy is important for scientific
progress and new discovery. The issue became clear when
electron microscopy (EM) studies could distinguish between
capillary lumen and end feet of astrocytes and proposed
that interendothelial TJ formed continuous, impermeable
membranes that contribute to the formation of BBB [27].
EM suggests the existence of BBB and functional unit of the
barrier is considered as NVU. Distribution of the barriers
in brain is shown in Figure 2. Later we will discuss how
target molecules or drugs cross this barrier and maintain
homeostatic balance.
3. Cellular Composition of NVU
Highly metabolic and dynamic activities of nervous tis-
sue may have been regulated by blood flow in the brain
through BBB, although the cellular mechanisms are not well
known [28]. Disruption of BBB integrity is accompanied
by neuropathological changes that indicate the selective
and compensatory event rather than a simple anatomical
disruption [29]. In case of Alzheimer’s disease, significant loss
of cholinergic innervations of cortical microvessels has been
observed that is due to impaired cerebrovascular function
[30].
The concept of BBB gradually evolved towards “extended
NVU” [31] that formed by astrocytes, pericytes, neurons,
microglia, capillary endothelium, immune cells, and the
extracellular matrix [3]. Physiological and pathological stim-
uli of NVU are affected by a complex molecular interaction
between cell-cell and cell-extracellular matrix and paracrine
cell-cell communication. Regulation of the local cerebral
blood flow, BBB permeability and transport mechanisms,
neuroimmune responses, and angiogenesis are principal
functions that are usually carried out by NVU [3]. Some
associated components of the NVU include the circulating
blood cells, such as polymorphonuclear cells, lymphocytes,
andmonocytes that adhere and roll along the vascular lumen
and perform surveillance of neural signalling and cellular
activity [32]. The CNS of invertebrate and lower vertebrate
provides evidence of the evolution of specialized glial cells to
pericytes and astrocytes at the vascular-neural interface [33].
Astrocytes are critical in the development and main-
tenance of BBB characteristics [34] and act as a linker
between endothelium and neurons. They also provide tropic
influence involved in the moment-to-moment regulation of
cerebral microvascular permeability [35] via Ca2+ signalling
and purinergic transmission [36, 37] as well as functional
response of NVU. In vitro culture of brain endothelial cells
with astrocytes has been shown to develop BBB character-
istics [38]. Pericytes usually located in between end feet of
astrocytes and endothelial cells. Presence of some contractile
proteins in cerebral pericytes indicates that they may be
involved in the regulation of capillary blood flow [39]. Cocul-
tures study indicates the role of pericytes for stabilization
of capillary-like structure [40]. In case of hypoxia [41] and
traumatic brain injury [42], pericytes have been noticed to
migrate away from brain microvessels due to increase BBB
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Figure 2: Distributions of barriers in brain. Neurovascular unit, choroid plexus, meninges, neuroependyma, and adult ependyma are the five
barriers that regulate dynamic balance between CNS and periphery. This figure is adopted from Neuwelt et al. [31].
permeability. Endothelial expression of occludin (BBB TJ
protein) may be induced by pericytes secretion of angiopoi-
etin that indicates the pericytes are involved in induction and
maintenance of barrier properties [43].
The extracellular matrix that serves as an anchor for the
endothelium also interacts with NVU. Disruption of this
matrix is compensated by increased BBB permeability [44].
Matrix proteins can influence the expression of endothelial
TJ proteins [45] that indicate the basal lamina proteins are
involved in the maintenance of BBB permeability.
In the last decades a significant understanding of NVU
associated cells and their molecular and pathophysiological
signalling has been developed. This progress is very crucial
for understanding neurological disorder and drug develop-
ment as well as delivery to the brain for the prevention
and treatment of the diverse neurological disorder. So, the
integrated cellular and molecular concept of the NVU may
be implemented in pharmacology and disease understanding
that related to cerebral microvascular permeability.
4. Molecular Features of NVU
Molecular interactions and signalling usually control the
major functions of NVU. Abnormalities of molecular level
show physiological change and consequently neurological
diseases. Proteins that associated with tight junction of
endothelial cells including junctional adhesion molecule-
(JAM-) 1, occludin, and claudins have significant role of
maintaining permeability. Although JAM-1 is a member
of IgG superfamily with large extracellular domain [46]
found in epithelial cells, JAM-2 and JAM-3 present in
endothelial tissues and lymphatic cells. Occludin has four
transmembrane domains that increase electrical resistance of
the tissue containing TJ [47]. Paracellular permeability of low
molecular proteins increases if C-terminal of the protein is
truncated [48]. Claudins have similar membrane topography
as occludin [49] and form the primary seal of the TJ; hence
occludin acts as additional support structure [1]. Some other
signalling molecules like Ca2+, cAMP, serotonin, cytokines,
chemokines, and steroids may affect BBB permeability. Some
endothelial transporters like P-glycoprotein and other pro-
teins of ABC transporter family are potential target for drug
design. Ablation of the gene encoding P-glycoprotein leads to
defective BBB transport and increased sensitivity to various
drugs [50]. As efflux transporter minimizes the drug efficacy
by reducing net drug penetration, it could be remodelling
target for drug delivery. Hypoxia-inducible factor- (HIF-) 1
is a transcription factor that induced associated gene expres-
sion to survive the cell in hypoxic condition [51]. Vascular
endothelial growth factor (VEGF) secreted by astrocytes
during inflammatory responsemay induce angiogenesis with
the help of other adhesion molecules [52]. Proangiogenic
NVUremodelling factors could be potential and considerable
target for future drug design and delivery. So the remodelling
of NVU during hypoxia may cause profound change of BBB
function and this strategy could be useful for drug delivery
by creating artificial short-term adjustment.
We have created a network (Figure 3) of 13 different genes
using GeneMANIA [53] which encode transporter protein
related to NVU.
5. Functional Characteristic of NVU
NVU has dynamic function to regulate BBB permeability
in the brain. CNS homeostasis is maintained by complex
transport mechanisms that adjust the balance between influx
of nutrients and efflux of wastes, toxins, and drugs [55].
Various factors regulate the barrier permeability of the NVU,
including membrane transporters and transcytotic vesicles
(Figure 4) [56]. Recent understanding of ion transporter pro-
teins and their role of fluid balance and water and electrolytes
movement by the cells of NVU has been expanded [31].
Presence of aquaporins in astrocytes end feet [57] indicates
their role in fluid dynamics and pathological consequences
may occur due to malfunction [58].
4 BioMed Research International
Table 1: Pathological consequences of NVU disorder.
Diseases BBB proteins and affected mechanisms
Alzheimer’s disease BBB disruption and permit peripheral IgG to brain. Decrease P-gp and accumulate amyloid-𝛽 inbrain [67].
Parkinson’s disease BBB disruption increases therapeutic agent concentration and reduces efficacy of Pgp [6].
Stroke Astrocytes secrete TGF𝛽 that downregulates tissue plasminogen activator (tPA) andanticoagulant thrombomodulin (TM) [68].
Epilepsy Transient BBB opening and upregulation of multiple drug resistance (MRD1) Pgp [69].
Trauma Opening of BBB, release of IL-6 from astrocytes, and neuroinflammation [70].
HIV BBB TJ disruption. Loss of glycoproteins and apoptosis of endothelial cell lead to increasediameter of cortical vessels [71].
Infectious processes Increase CSF/serum albumin ratio. Bacterial lipopolysaccharides affect BBB TJ [72].
Brain tumours Breakdown of BBB TJ, overexpress folate, insulin, and transferrin receptor, and downregulation ofclaudin 1/3 [73].
Ischaemic brain oedema BBB breakdown due to MMP9 release by neutrophils and degradation of occludin, claudins, andJAM [74].
Functions legend
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Figure 3: BBB transporter gene network. Gene network constructed
with the help of GeneMANIA [54] tools. Black circles represent the
transporter genes and gray circles represent the genes that related
to the transporter genes. SLC gene family is actively linked to BBB
transportation.
Xenobiotics resistance to brain is another important
function ofNVUmaintained by two components of endothe-
lial cells: efflux transporters and tight junctions [31]. P-
glycoprotein (Pgp) transportation is regulated by efflux trans-
porters. Paracellular diffusion of water-soluble solutes and
drugs, from blood to brain, is restricted by tight junctions
[40].
Signalling between neurons and astrocytes may influ-
ence cerebral blood flow [60]. Astrocytic calcium signalling
triggered the vasoactive messengers [37] that alter local
cerebral blood flow. Pericyte-endothelial cell interactions
regulate some properties of the BBBduring development, and
disruption of these interactions may lead to BBB dysfunction
and, thus, to neuroinflammation as part of the response to
CNS injury as well as consecutive diseases [61].
6. Disease Aetiology of NVU Abnormalities
Abnormal NVU selective permeability function may cause
various CNS diseases (Table 1). The capillaries of brain
tumours are more leaky than normal brain tissue [62].
During the process of aging, several vascular risk factors
including hypercholesterolemia, hypoglycemia, and hyper-
tension damage the NVU leading to chronic hypoperfusion,
BBB dysfunction, and common NVU pathophysiological
responses [63]. Alzheimer’s disease (AD) patients have more
strokes than age-matched controls [64] that indicate a cor-
relation between NVU disorder and AD. VEGF disrupt
TJ and increase BBB permeability. Migrating endothelial
cells and pericytes release metalloproteases that may disrupt
basement membrane [3]. Influx of serum proteins (albumin,
thrombin) and water (through the disrupted membrane) is
responsible for liquid accumulation that causes oedema and
triggers astrocytic response. Some recent data suggest that
acute increase of BBB permeability changes the extracellular
ionic environment that promotes high synchronicity and
excitability of neuronal network [65, 66] and contributes to
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Figure 4: Pathways across the blood-brain barrier. Endothelial cells and end feet of astrocytes that form NVU contain five trafficking routes.
Only a handful of drugs can cross BBB. Although most CNS drugs enter via lipophilic rout (size no longer than 600Da), pharmacological
targets are another three pathways to efficient drug delivery. The figure is adopted from Abbott et al. [59].
glial immune response that might be a causative agent of
epilepsy.
7. Diagnostic and Therapeutic Target of NVU
There are sufficient evidences that BBB disruption is the early
event in many neurological disorders; growing interest of
therapeutic target on that region is not unusual [75, 76]. Acute
neuroinflammatory impact of BBB due to traumatic brain
injury has substantial role in drug targeting, as some animal
studies [77, 78] already found the initiation of transcriptional
changes in neurovascular network for BBB breakdown that
leads to neurodegeneration [79].
Whether we could stop neurodegeneration by inhabiting
inflammatory cytokines is the next focus of study. Anakinra
is the inhibitor of interleukin 1 (IL-1), successfully used
for rheumatoid arthritis treatment [80]. Nonsteroidal anti-
inflammatory drugs (NSAIDs) are another successful exam-
ple based on inhibitory mechanism that is being used for
Alzheimer’s disease [81]. So, we can say that BBB disruption
based neuroinflammation could be a potent therapeutic
target.
As varieties of neurological diseases are linked to NVU,
continuous research efforts might lead to identifying specific
biomarkers and to developing therapeutic strategies to con-
trol the abnormalities. Due to accessibility and expression
in early stage, vascular compartment specific molecular
biomarkers are attractive and can be detected in situ using
molecular imaging or in the circulating compartment using
“omics” approaches [3]. Angiogenic brain tumour can be
identified by microarray analysis of specific markers [82].
Monoclonal antibody based treatment of multiple scleroses
which binds the 𝛼4 integrin receptor found on leukocytes
that prevents adhesion of the leukocytes to brain endothelial
cells [83]. Protection of BBB integrity by inhibiting metallo-
protease could be therapeutic treatment of stroke [84].
Combination of L-DOPA and carbidopa is the potential
drug used for Parkinson’s disease but bioavailability of oral
dose is less than 1% due to efflux pump [1]. Donepezil
is acetylcholinesterase inhibitor that can treat Alzheimer’s
disease, but P-gp mediated efflux limits therapeutic con-
centration [85]. Refractory epilepsy does not respond to
antiepileptic drugs because of increased expression of P-
gp and multidrug resistance efflux pumps [86]. Brain can-
cer treatment is also difficult for limited accessibility of
chemotherapeutic agents to BBB.
Dexamethasone is being used for brain oedema that
regulates P-gp expression and constrains TJ in brain endothe-
lial cell [87]. Differential display technique gives us the
idea of disease causing gene expression that could be target
for therapy [88]. A gene network of transporter protein is
already shown in Figure 3. Intraventricular administration of
VEGF increases endothelial permeability (possibly involving
activation of the PI-3-Akt pathway) that might act through
BBB associated cells [89]. So, we can easily say that NVU is
not the only emerging area; associated capillary endothelial
cells of BBB also could be future diagnostic and therapeutic
target of neurological disorders [90].
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8. Modern Pharmacological Approaches of
NVU Based Drug Delivery
Amajority of well-known drugs give only symptomatic relief
for a limited period with adverse side effect and toxicity.
Around 98% of small drugs and nearly 100% of large drugs
molecules cannot penetrate the brain in sufficient therapeutic
amount [91]. There is no meaning of a drug if it cannot be
transported across the BBB.
Prodrugs like L-DOPA could penetrate through carrier
mediated transport when targeting endogenous transport
protein.Molecular Trojan horses use receptor-mediated tran-
scytosis (RMT) that could permit large molecule to the brain
[92]. Insulin receptor could be a better candidate for drug
delivery with human insulin monoclonal antibodies which
works 900% more actively and 10 times more effectively in
comparison to transferring receptor [93]. But efflux pumps
of astrocyte have limited squeezing efficacy in case of larger
molecules [94]. Liposomes are good drug transporter and
enhance bioavailability of the drug. DepoFoam is an advance
liposome that performs continuous release of drugs with
noninvasive strategy. This technique poses a great potential
for CNS drug delivery with lower dosing and better efficacy.
Although fewer side effects have been reported, none of
those were severe [95]. Insulin, lipoprotein, and diphtheria
toxin receptors are potential for molecular delivery in brain.
Another relatively new approach is cell mediated transcytosis
that is considered the outcome of rapid progress of molecular
biology. Gene therapy is another molecular technique that
could replace disease causing gene in the cell. Transport
vectors could activate natural transport rout and enhance
entry to the brain. Clinical use of gene therapy is still limited
due to immunogenic safety issue [96]. So, ion channels,
neurotransmitters, growth factors, and transcription factors
are prospective therapeutic targets for new drugs delivery.
Our recent understanding of cellular receptor and poly-
mer chemistry brings a new field of drug delivery called
nanotechnology. This nanoparticle could be transported in
various parts of body and deliver drugs including brain
[97]. Modified surface properties of the particle can carry
different types of drugs to different part of our body. One
of the important components of nanoparticles is Human
Serum Albumin (HSA) that can be modified and works
without serious side effect [98]. Some nanoparticle based
cancer drug delivery is still in clinical trial. In spite of being
a potential field of drug delivery, a handful of nanoparticles
are preclinical evaluation due to small size, aggregation, and
physical handling difficulties [99]. However, there might
be many threatening possibilities for especially long-term
impact of such drugs and metabolism of the particle should
be considered carefully.
9. Computational Approach of
Drug Design and Delivery
New drugs development and increase of the existing drugs
efficacy are the major challenges of pharmacology. Tradi-
tional drug designing protocol is time-consuming, risky, and
indeed costly. Katara [100] described the role of bioinfor-
matics and pharmacogenomics for drug design but not BBB
oriented drug delivery. We integrate the recent approaches of
target based drug. Computational biology is a new field that
emerged in the last decades and integrated to pharmacology
due to assist drug design and delivery.We cannot think about
personalized medicine without another increasing branch
called pharmacogenomics [101].
Recently P-gp is being used as therapeutic target for
optimizing CNS drug delivery that is based on pharma-
cogenomics data analysis [102]. Pharmacogenomics refers
to the effects of single nucleotide polymorphism (SNP)
and copy number variation (CNV) on drug response; its
knowledge can help in selection of the optimal drug, dose,
and treatment process and avoid adverse drug reactions
[103]. The PharmGKB is a pharmacogenomics knowledge
resource that comprehends clinical information, clinically
actionable gene-drug associations, and genotype-phenotype
relationships [104]. Integration of this entire branch can
accelerate various steps of drug designing and reduce the time
as well as overall cost.
Constant pressure of generating various drugs within
limited time period with low risk has resulted in remark-
able interest in bioinformatics [105]. The major benefits of
bioinformatics are to sort out the biologically active and
potential candidates and predict and identify their biological
phenomena using data mining [106]. Human genome project
gives us the available public data [107] for mining and
generating valuable data for computer-aided drug design and
delivery approaches that greatly increase the potential drugs
candidates in the pipelines of pharmaceutical companies
[105, 106]. Store and analysis of those huge data are not easy
and computer scientists bring out a solution called cloud
computing. Several drug target databases are available online.
DrugBank is a comprehensive drug information database
that works based on bioinformatics and chemoinformatics
data [108]. SuperTarget is a 2D drug screening and sequence
comparison database for the extensive drug target [109].
Search Tool for Interactions of Chemicals (STITCH) and
Ingenuity Pathway Analysis (IPA) are the searchable database
that summarizes information from text mining, metabolic
pathway, drug target relation, and structural similarity [110].
Therapeutic Target Database (TTD) is a therapeutic target
database that provides information of known therapeutic
protein and nucleic acid [111].
In spite of drug target validation, bioinformatics provides
different algorithms that reduce the failure of clinical trial
approaches [112]. Physiology of experimental lab animals
and human being is not the same which could be a notable
burden for the final stage of clinical trial. Computational
biology gives us the in silico validation and docking analysis
opportunity before further step.
We have the genomic data and we know the cellular
composition of NVU as well as transporter proteins. So
we could in silico validate the drug candidates regarding
efficacy to brain and accessibility to BBB. TJ is the main
regulator of NVU permeability and we know the structural
composition of TJ associated proteins. Howwe could regulate
and adjust the short-term opening of TJ is a burning question
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of drug delivery to brain. Also there is extensive study area
of surrounding cell physiology and molecular function that
might give us details and integrated view.
Pharmaceutical companies are focused on blockbuster
drugs prescribed to more than 20 million people. Recent
Ebola outbreak in Africa shows us the necessary of orphan
drug development. This raises an issue for developing coun-
tries and bioinformatics could be the possible hope for the
orphan drug development as per need [113].
Nowadays it is quite easy to identify drug candidate
and target using online database but experimental validation
is not easy. Although bioinformatics is a potential field, it
did not bring any considerable change yet for drug design
and delivery process. This is due to less acceptance of new
technology and lack of technical expertise. Also changing the
traditional drug market is a big issue for the pharmaceutical
companies and investors. We can expect that in the near
future the situation will change and bioinformatics based
drug design and delivery through NVU will be popular and
time- and cost-effective with high level of drug efficacy.
10. Conclusions
We still have limited knowledge of the human brain andmost
of its functions that remain unknown or mysterious. This
paper has described the role of NVU in CNS homeostasis
and potential target for therapies. Bioinformatics and phar-
macogenomics can provide huge support for pharmaceutical
companies in order to design drug for neurological disorder
with reasonable time and affordable cost. Drug trials might
have some limitation in order to measure the functionality
of therapeutics. We need to minimize the gap between cell
culture and animal model study to get appropriate under-
standing of drug delivery. Application of molecular biology
into neuroscience could help to understand genetic make-
up, epigenetic variation, and near prospect of personalized
medicine. Integrated systembiology approaches could help to
know insights into disease aetiology, progression, and target
oriented cocktails drugs design. Although bioinformatics and
pharmacogenomics are passing initial phase of development,
they already pose enough potential for future drug industry.
Brain targeted drug delivery must be safe and beneficial
for patients and have to ensure minimum short- or long-
term impact. Finally, it can be said that NVU would be the
main target of pharmacokinetics to reduce drug abuse and to
answer some unsolved questions of neuroscience.
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